<DOC>
	<DOCNO>NCT00289445</DOCNO>
	<brief_summary>The aim study define maximum tolerate dose ( MTD ) bolus mitomycin C ( MMC ) combination 24 h-continuous infusion 5-fluorouracil ( FU ) plus folinic acid , assess toxicity activity patient previously treat colorectal gastric cancer . Escalating dos MMC start 6 mg ( -2 ) 2 mg ( -2 ) -steps maximum 10 mg ( -2 ) apply day 1 22 , give fixed dos 5-FU ( 2.600 mg ( -2 ) ) 24 h infusion folinic acid 500 mg ( -2 ) prior 5-FU weekly 6 week</brief_summary>
	<brief_title>Study With Mitomycin c/5-FU/FA Pretreated Gastrointestinal Cancer Patients With Metastases ( &gt; = Second-line Treatment )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Phase 1 ( dose escalation ) patient histological proven gastrointestinal neoplasm , without standard therapy option measurable evaluable disease &gt; = secondline therapy ( metastasized stage ) Phase 2 ( efficacy ) patient proven colorectal neoplasm measurable disease , metastasize previous chemotherapy 5FU/FA ( `` AIOregimen '' ) age 18 75 year , male female life expectancy &gt; 3 month WHOperformance status &lt; = 2 adequate bone marrow function : hemoglobin &gt; = 10 mg/dl , neutrophils &gt; = 2.0 * 1000000000/l , thrombocyte &gt; = 150 * 1000000000/l adequate renal liver function : bilirubin &lt; = 1.25 * ULN ( &lt; = 1.5 ULN * liver metastasis ) , creatinine &lt; = 1.25 * ULN , ASAT ALAT &lt; = 3 * ULN ( &lt; = 5* ULN liver metastasis ; AP &lt; = 3* ULN write informed consent prior inclusion study pretreated mitomycin c contraindication concern 5FU ( e.g . anxiety , myocardial infarction within last 6 month , significant toxicity previous therapy 5FU florid infection ileus subileus , morbus crohn colitis , ulcerative actual chronic diarrhea uncontrolled severe concurrent disease exclude cytotoxic intervention second malignancy except basal cell carcinoma cervical carcinoma situ know cns metastasis carcinomatous leptomeningitis pregnancy lactation period effective contraception concomitant treatment another antineoplastic agent participation another clinical trial within last 4 week patient unwilling unable undergo trial specific procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>